title: Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants.
abstract: Modulation of glutathione has been proposed as a mechanism to alter the efficacy and toxicity of chemotherapeutic agents. We investigated in vitro cytoenhancement of chemotherapy toxicity by reducing cellular glutathione levels with L-buthionine-[S,R]-sulfoximine (BSO), and chemoprotection with small molecular weight sulfur-containing agents that mimic or replace glutathione. Cytotoxicity, caspase-2 enzymatic activity, and in situ DNA staining for apoptosis were assessed in cultured human small cell lung carcinoma cells and fibroblasts. BSO treatment reduced the half-maximal cytotoxic dose of the alkylating chemotherapeutics melphalan, carboplatin, and cisplatin, and increased the total magnitude of cell death. Melphalan was more sensitive than carboplatin or cisplatin to BSO. The chemoprotective agents sodium thiosulfate, N-acetylcysteine, and glutathione ethyl ester reduced the cytotoxicity of all three alkylating chemotherapeutics regardless of BSO treatment, but D-methionine was effective only against the platinum agents. N-Acetylcysteine was the most effective protectant tested. Chemoprotection against melphalan toxicity was maximally effective only if administered concurrent with chemotherapy, whereas chemoprotection for the platinum agents remained effective if delayed 4 h after chemotherapy. BSO enhancement and N-acetylcysteine chemoprotection for melphalan toxicity occurred at least partially through an apoptotic mechanism. Modulation of glutathione levels will be valuable in the clinical setting if chemotherapy and chemoprotectant can be physically and/or temporally separated. Cytoenhancement and chemoprotection may be particularly useful in the central nervous system where the blood-brain barrier of the cerebral vasculature creates two compartments, for cytoenhancement in brain tumors and systemic chemoprotection.
authors.affiliation: Department of Neurology, Oregon Health Sciences University, Portland, Oregon 97201, USA. muldoonl@ohsu.edu
authors.forename: L L
authors.initials: LL
authors.lastname: Muldoon
authors.forename: S L
authors.initials: SL
authors.lastname: Walker-Rosenfeld
authors.forename: C
authors.initials: C
authors.lastname: Hale
authors.forename: S E
authors.initials: SE
authors.lastname: Purcell
authors.forename: L C
authors.initials: LC
authors.lastname: Bennett
authors.forename: E A
authors.initials: EA
authors.lastname: Neuwelt
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology; D000477:Alkylating Agents / Q000494:pharmacology*; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis; D019328:Buthionine Sulfoximine / Q000494:pharmacology*; D016190:Carboplatin / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D019610:Cytoprotection; D004347:Drug Interactions; D006801:Humans; D008970:Molecular Weight; D020011:Protective Agents / Q000494:pharmacology; D013885:Thiosulfates / Q000494:pharmacology*; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D000477:Alkylating Agents; D000964:Antimetabolites, Antineoplastic; D020011:Protective Agents; D013885:Thiosulfates; D019328:Buthionine Sulfoximine; D016190:Carboplatin; C017717:sodium thiosulfate; D000111:Acetylcysteine